



City Research Online

City, University of London Institutional Repository

Citation: Harris, J., Purssell, E., Ream, E., Jones, A., Armes, J. & Cornelius, V. (2020). How to Develop Statistical Predictive Risk Models in Oncology Nursing to Enhance Psychosocial and Supportive Care. *Seminars in Oncology Nursing*, 36(6), 151089. doi: 10.1016/j.soncn.2020.151089

This is the accepted version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/32063/>

Link to published version: <https://doi.org/10.1016/j.soncn.2020.151089>

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

City Research Online:

<http://openaccess.city.ac.uk/>

publications@city.ac.uk

How to develop statistical predictive risk models in oncology nursing to enhance psychosocial and supportive care

Jenny Harris¹ BSc, MSc, PhD

Edward Pursell² RSCN, RGN, BSc, MSc, PhD

Emma Ream¹ RGN, BSc, MSc, PhD

Anne Jones³ RGN, PGCAP, MSc, PhD

Jo Armes¹ RGN, BSc, MSc, PhD

Victoria Cornelius⁴ BSc, PhD

Affiliations

1. School of Health Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey.
2. School of Health Sciences, City, University London, UK.
3. Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK.
4. Imperial Clinical Trials Unit (ICTU), School of Public Health, Faculty of Medicine, Imperial College London, London, UK.

Corresponding author:

Name: Dr Jenny Harris

Address:

Dr Jenny Harris
School of Health Sciences
University of Surrey
Faculty of Health and Medical Sciences
Duke of Kent Building,
Guildford,
Surrey
GU2 7XH

Keywords: predictive risk models, regression models, cancer, psychosocial, supportive care, psychological, distress

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Availability of data and material: Not applicable.

Declarations of competing interests: None.

Funding: JH was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Authors contributions: JH drafted the manuscript. VC drafted and commented on the direction of the manuscript and provided statistical oversight. All authors read and commented on drafts. All authors read and approved the final manuscript.

Acknowledgements: We would like to thank Independent Cancer Patients' Voice and KCL's Supportive Cancer Care group for their feedback on our research.

Objectives Predictive risk models are advocated in psychosocial oncology practice to provide timely and appropriate support to those likely to experience the emotional and psychological consequences of cancer and its treatments. New digital technologies mean that large scale and routine data collection are becoming part of everyday clinical practice. Using this data to try to identify those at greatest risk for late psychosocial effects of cancer is an attractive proposition in a climate of unmet need and limited resource. In this article we present a framework to support the development of high-quality predictive risk models in psychosocial and supportive oncology. The aim is to provide awareness and increase accessibility of best practice literature to support researchers in psychosocial and supportive care to undertake a structured evidence-based approach.

Data sources Statistical prediction risk model publications.

Conclusions In statistical modelling and data science different approaches are needed if the goal is to predict rather than explain. The deployment of a poorly developed and tested predictive risk model has the potential to do great harm. Recommendations for best practice to develop predictive risk models have been developed but there appears to be little application within psychosocial and supportive oncology care.

Implications for nursing practice Use of best practice evidence will ensure the development and validation of predictive models that are robust as these are currently lacking. These models have the potential to enhance supportive oncology care through harnessing routine digital collection of patient reported outcomes and the targeting of interventions according to risk characteristics.

Introduction

Oncology nurses have an important role in delivering high quality and compassionate psychosocial and supportive care for people living with and affected by cancer.¹ An integral part of the cancer multi-disciplinary team (MDT) nurses are particularly well-placed to provide practical, informational, and emotional support in response to symptom and distress screening² and on-going needs assessments.^{3,4} The advent of digital health and increasingly routine collection of patient reported outcomes (PROs)^{5,6} present greater opportunities for oncology nurses to incorporate real-time patient feedback and probability-based risk assessments into their psychosocial and supportive care plans.

Predictive risk models (PRMs) also known as clinical prediction models, nomograms, risk indexes or rules⁷ are designed to predict an individual's risk of having - or developing - a specific condition or outcome based on multiple variables.⁸⁻¹¹ Well-known PRMs are used in practice to target the most appropriate screening programmes, care and treatments according to future risk such as the BOADICEA model used for risk stratification for breast cancer in the general population and for women with family history¹² and the Nottingham Prognostic Index (NPI)^{13,14} or Adjuvant! Online^{15,16} for the management of breast cancers. In cancer care, as with most areas of healthcare, the focus has been on developing PRMs related to primary disease outcomes such as death and occurrence or remission of disease.¹⁷

However, other outcomes relevant to on-going quality of life are beginning to receive more attention⁹ including within supportive oncology.¹⁸⁻²¹

Developing PRMs to inform oncology nursing practice can be useful to inform and enhance follow-up care through heightened clinical awareness⁹ or PRMs can be used alongside on-going needs assessments to target care.^{22,23} Furthermore, as shared decision-making forms the cornerstone of modern oncology nursing practice,²⁴⁻²⁶ PRMs have the potential to provide an evidence-based input to support shared decision-making²⁷ and patient-centred communication, particularly in the context of nurse led follow-up consultations and in considering supportive care options.²⁸

However in psychosocial and supportive oncology model development, practice is not optimal and there appears to be a lack of awareness around differences between developing models for valid explanatory purposes (that is, causation or inference) and building powerful predictive models.^{9,29,30} Our systematic review on predictors of anxiety after breast cancer treatment found that most existing research was cross-sectional, lacked reproducibility (including any model validation or testing in different contexts) and relied on methods best suited to explanation rather than prediction.¹⁸ This focus on explanatory models is understandable; those involved in psychosocial oncology and supportive care research are more familiar with explanatory modelling as the goals are often to seek to unpick the underlying mechanisms, to develop or confirm theories, and to identify treatments or interventions to target these mechanisms.³¹ Additionally, training in most elementary courses in quantitative methods in health sciences cover only statistical inference (explanatory mechanisms) not prediction models.

Examples from across different sectors including health and social care demonstrate that the failure to apply best practice standards can lead to sub-optimal models³² and the

deployment of poorly developed and inadequately tested PRM that can lead not only to biased models ('garbage in, garbage out')³³ but sub-optimal practices and care, outcomes and result in real harms to individuals.³⁴⁻³⁶

In order to develop powerful and safe predictive models for use in routine practice a different approach is required, with less emphasis on null hypothesis significance testing (NHST) and greater emphasis on avoidance of overfitting the model to the nuances of the data. In this article we firstly explain why different approaches to model development are needed and then present a framework for psychosocial and supportive care oncology researchers to describe best practice for PRM development using a structured evidence-based approach. By providing this framework we hope to encourage greater uptake of good statistical practice. We draw on our own experience from using patient reported outcomes and data, key literature and best practice recommendations developed within the statistical community,^{7,23,27,37-44} the latter of which have received relatively little application within the psychosocial and supportive cancer care. The intention is that this article will provide a useful, accessible framework for a non-statistician oncology audience and related professionals involved in psychosocial oncology care and research.

Focus on prediction, not explanation

Many researchers conceptually conflate explaining phenomena with the ability to generate robust predictions.^{27,30} The roots of this may lie in the dominance of hypothetico-deductive modelling (falsification) and inferential hypothesis testing⁴⁵ which is core to statistical training in nursing and health sciences⁴⁶ which tends to equate the two. Predictive modelling is characterised by some notable elements summarised in Table 1.

Overall, three main types of models for prediction can be identified: regression, classification and neural networks.²⁷ Here we focus on regression-based statistical techniques as they are mostly widely used in oncology nursing. Those interested in AI approaches to machine-learning should refer to recent and upcoming EQUATOR guidance.⁴⁷⁻⁴⁹

A guide good practice in predictive risk model development

A series of landmark articles recommended three main steps that should be completed before PRMs are used in routine clinical practice: 1) developing the model, 2) validating statistical performance and 3) evaluating clinical performance.^{7,9,23,37,38,50,51} Criteria for reporting the development of such models was further established by the EQUATOR network provided by the transparent reporting of multivariable prediction model for individual prognosis or diagnosis (TRPOID) statement^{37,51} and the American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine established their own endorsement criteria.⁴³ The article focuses on the **development phase** including two distinct stages **preparation for modelling** describing three key processes and **analysis and modelling** describing six key processes. Some of the processes are iterative and overlap, although for ease of explanation they are presented sequentially here.

Preparation for modelling

1. *Choosing and defining an outcome*

Predictive risk models estimate the probability of an outcome⁵¹ and so the first step involves not only identifying an outcome to be predicted but defining its key parameters of interest.

For example, for a researcher interested in long-term neutropenic symptoms this could include occurrence (classified as present/absent), severity of symptoms (rated on a patient reported outcome scale), progression or change in symptoms over-time (repeated-measures) or the absolute number of discrete symptoms (counted). All may be important depending on the specific research question, condition, domain or time-horizon of interest. Choosing the most appropriate outcome will help identify potential data sources and determine modelling strategies. In psychosocial oncology the parameters of outcomes should be both clinically meaningful and patient focused (see process 2) and will likely be informed by pragmatic concerns and local clinical context.

Other important parameters to consider when choosing an outcome are the availability of valid and reliable measurements including considering administration/collection mode, type of outcome (single/combined), duration and number and the timing of measurements of outcome.⁵² Linked to this is the need to clearly define clinically meaningful time horizon from baseline (time-origin) to the eventual outcome prediction time-point.⁴²

In order to develop powerful PRMs, wherever possible researchers should avoid the temptation to apply dichotomies without careful consideration and/or arbitrary cut-offs of scales. In prediction research there is a strong tendency to classify outcomes so that individuals are 'a case' or 'not a case'. Such approaches to dichotomisation, requiring use of logistic regression models to analyse this data, should generally be avoided in the development phase if the outcome is not a discrete event in order to avoid residual confounding (which occurs when there is inadequately adjustment for a variable in a model).^{40,53}

The emergence of digitally assisted data collection techniques in practice means it is no longer necessary for researchers to impose arbitrary 'cut-offs' in model development, where a score above an arbitrary threshold is determined to be a 'case'. Instead, if patient or clinician usability/acceptability requires risk grouping, appropriate thresholds should be determined through implementation studies if risk grouping is necessary after development phase.

2. *Reviewing current knowledge and clinical practice*

In order to fully understand the context in which the model will be used and assist with some modelling decisions such as selecting candidate predictors, a thorough review of the literature, and investigation of current practice and patient perspectives should be undertaken.

The identification of candidate predictor variables⁵⁴ should be achieved through an in-depth review of current evidence and assessment of clinical practice including grey literature and local and/or national policies and provision. Reflecting the scope of oncology nursing practice, candidate predictors are unlikely to only involve patients' biomedical characteristics (tumour type and grade, metastases) but will typically span biopsychosocial domains of health.^{18,55} The formal identification of candidate predictors should be informed by a risk prediction systematic review⁵⁴ which uses specific methodologies focused on identifying and evaluating the strength of evidence from studies with longitudinal designs and multivariable analysis to distinguish the variables most strongly associated with an outcome of interest.^{29,52,56,57} When evaluating the evidence-base for statistical models it is important to assess original research against quality standards. The Quality in Prognosis Studies (QUIPS)

tool provides a useful basis by which to systematically assess quality of previous research and thereby the strength of evidence.^{39,58}

The involvement of people affected by cancer, cancer care professionals and other stakeholders is also an essential component in developing models that are relevant and usable in practice.⁸ Patient and public involvement (PPI) in the development of PRM should be viewed as a priority³⁸ and reported according to best practice.^{59,60} This particularly important for PRMs designed to inform supportive cancer care as acceptability (patient and clinicians subjective views) and feasibility (for example, ease of use and assessment in clinical setting) are often overlooked but are crucial if a PRM is ever to be implemented in routine clinical practice.⁸ Similarly high quality PPI is likely to becoming increasingly important in light of issues around ethical issues about the use of data, regulation and legislation, such as General Data Protection Regulation (GDPR) in the European Union. More formal techniques for establishing clinical consensus such as focus groups, expert surveys or modified Delphi,⁶¹ may be required where evidence is unclear or original research is lacking.

3. *Assessing the data quality*

In this section we detail three key sub-processes useful in determining high quality data sources for predictive models. In the age of open science and open data, this may not only include original comprehensive observational research⁹ designed specifically for the purpose of developing PRM but increasingly secondary analysis of existing research data⁶² and/or routinely collected data (e.g. electronic health records) at a local or national level and/or data linkage through digital technologies³⁸. However, some key challenges exist with use of routine data including losses to follow up (missing data), errors or validity of coding/classifications, and ethical data protection issues around access, consent and use of

data.⁶³ As with any analysis it is important to be able to understand and describe the specific cancer diagnosis of the patients on which the PRM was developed and any inclusion/exclusion criteria used so users can understand the applicability of the model to individual patients.⁴³

3.1 Longitudinal design and data sources

It is common for psychosocial oncology studies to describe results as 'predictive' when in reality they are correlational due to using a cross-sectional study design (even if using a regression-based modelling approach).¹⁸ If we are to build powerful PRM to inform the decision-making of people living with cancer and to guide their supportive care pathways, models should be built on longitudinal data. This could include prospective data collection, retrospective or some combination of both. As longitudinal research is expensive, an acceptable and efficient solution is to use pre-existing datasets for secondary analysis.⁶² Ideally data would be observational (this could incorporate routine data and patient records).⁹ Secondary analysis of trial data can be appropriate in psychosocial and supportive care research, but case control data should be used with caution because participants are selected based whether an outcome was achieved and so their risk profile may not reflect the target population.⁴²

When designing a new study or secondary analysis, multiple candidate predictors need to be measured at an appropriate 'baseline' and the outcome(s), time-horizon predicted, measured after a sufficient interval.^{42,64} These time-horizons will depend on the research question and intended purpose of the model being developed. For example, a PRM designed to predict health-related quality of life (HRQoL) after adjuvant chemotherapy for women with breast cancer might include baseline measurements (such as demographic, clinical characteristics

and baseline QoL) before or at the start of treatment plus time-dependent covariates (occurrence of symptoms/toxicities during the first 6 cycles of treatment), to predict HRQoL 3-months after treatment has completed. In this example, this time-horizon might be chosen as a patient-focused and clinically relevant time-point to coincide with the timing of the nurse led post-chemotherapy follow-up appointment.

3.2 Candidate predictors

Data sources should include important candidate predictors (informed by processes 1 and 2) and will often include routinely collected patient characteristics such as age, sex, comorbidities and baseline measurement of outcome. Where secondary analysis is involved it is likely that some important candidate predictors will be omitted from the data source and this should be acknowledged as a limitation. As with any study it is important to ensure that measurements are valid/reliable for the target population including those that are routinely collected.^{38,64} Candidate predictors can be interval, ordinal or nominal but the transformation of variables from continuous to categories should generally be avoided to develop robust models and avoid residual confounding.^{27,40,65} As with outcomes, in psychosocial oncology candidate predictors should be both clinically meaningful and their inclusion will likely be informed by similar pragmatic concerns and local clinical context. For example, in practice PRMs are unlikely to be adopted if the baseline measurement required is difficult to measure or requires additional resource to collect.⁸

3.3 Sample size

To develop robust PRM and avoid overfitting the model to the data, an appropriate sample size is required in terms of the number of participants relative to the number of candidate predictors.⁵⁰ In this context it is not widely understood that traditional 'power calculations'

are inappropriate because there is no hypothesis test.⁵⁰ For binary (categorical) or time-to-event outcomes in the past the general *rule of thumb* for sample size was 10 events (i.e. 'cases') per candidate predictor in the model.⁵⁴ However, this is now understood to be more complex,⁶⁶⁻⁶⁸ in certain circumstances this could be lower⁶⁹ and more recent publications have shown the number is often likely to be much higher.^{50,70,71} There are similar and complex considerations for linear regression models where traditional approaches to sample size calculation often underestimate numbers required and will fail to achieve necessary precision.⁷² Specifically, researchers will often underestimate the sample size required in the presence of categorical predictors which are common in psychosocial and support care research.⁷² In certain circumstances the effects of a low events-per-predictor may be mitigated with modern regression shrinkage techniques (discussed later) but their application requires careful consideration. Therefore, our advice is that sample size rule of thumbs should be avoided. We recommend using Riley et al⁵⁰ 4 step guidance on calculating sample sizes for PRM and that expert advice should always be sought when considering sample sizes for prediction, to ensure precise estimates of predictors, avoid overly optimistic model and reduce overfitting.

3.4 Establish type of multivariable regression method

The outcome of interest will determine the type of regression model to use. For continuous outcomes, a linear regression model is often developed to predict an outcome value based on the values of multiple predictors which can be continuous, dichotomous or categorical.⁷² For binary outcomes logistic regression models are developed to predict an event as present or absent conditional on values of multiple predictors. Other classes of regression used in oncology research include Cox's proportional hazard regression models (the time for the event (outcome) to occur) and less commonly Poisson regression models (for counted outcomes

data) and polynomial (where outcomes are continuous but associations are not assumed to be linear). The key message is that the type of model will be determined by the research question, choice of outcome and the data source.

Advances in modern computing and data science mean that researchers can also consider using newer regression techniques that may be more appropriate for developing generalisable PRM. Penalised (shrinkage) regressions such as Ridge,^{73,74} LASSO⁷⁵ or Elastic Nets⁷⁶ all introduce a penalty term into the regression and can help reduce overfitting. These approaches may particularly useful for; identifying predictors of 'rarer' psychological outcomes or symptom profiles in cases of low events per predictor,⁷⁷ where there is multicollinearity of predictors and situations where parsimonious models may be more practical and variable selection is required.⁷⁸

Prior to commencing analysis, a statistical analysis plan (SAP) should be written, preferably in consultation with a medical statistician, to avoid data dredging (where large values of data are analysed and any spurious associations are presented as important)⁷⁹ and deviations from this plan should be noted in any publications.⁸⁰ In some cases, including PRM using data linkage and big data, the involvement of data managers, computer and/or data scientist will also be important.

Analysis and modelling

4. *Assess data quality*

As with all analyses, is important to first use descriptive statistics to get to know the data and describe the sample, if possible, compared to known population estimates.⁵¹ This is important because systematic biases in data may lead to biased models. For example, in our experience in psychosocial oncology people from black and minority ethnic communities are

often under-represented in datasets⁸¹ and so in assessing the utility we should have an awareness of inherent biases with respect to the individual.

Many research and clinical datasets have missing data and so it is essential to explore the amount, patterns and mechanism of missingness.⁸²⁻⁸⁶ It is often unrealistic to assume that the values for missing data for patients are the same as those with complete data, particularly in cancer, where patients often experience multiple-morbidities alongside social, economic and psychological challenges. Failure to analyse missing data may result in biased prediction models⁸² and many software packages readily support exploration of missing data with built in functions to assist with this. The quality of data may affect the ability to include candidate predictors, for example if a potential predictor includes a high amount of missing data or lacks variability (floor-ceiling effects).⁴⁰ Where this is the case this should always be acknowledged as a methodological limitation.

5. ***Handle missing data***

The best approach to missing data is to try to avoid it in the first place, through better design and data collection methods, however missing data is an inevitable part of health research or clinical datasets^{82,84-86}. Furthermore, as much research in psychosocial oncology involves patient reported outcomes and other measurement scales derived from self-report questionnaires, data can be missing in many ways, including for outcomes and predictors, and at the item level or for complete questionnaires or scales.⁸² For PRO and questionnaires, original authors guidelines should be consulted to handle item level missingness, however we have found that some widely used measures, such as the Hospital Anxiety and Depression Scale⁸⁷ provide no guidance on handling missing data and specialist statistical studies may need to be consulted where they exist.⁸³

Unfortunately, in psychosocial oncology model building typically relies on only patients with complete data, so called case-wise deletion, even when more than 5% of data is simultaneously missing.¹⁸ This should generally be avoided, as should mean or single imputation which reduce efficiency of data use and increase bias⁸⁸ as these methods assume data is missing completely at random which is often unrealistic. There are alternative approaches that make less strong assumptions for the missing data. One of these is Multiple Imputation using Chained Equations (MICE)^{89,90} that makes a missing at random assumption and provides a flexible approach to missing data. This can be implemented using statistical software (including SPSS, SAS, Stata and R) and is well suited to longitudinal data generated using patient reported outcomes.

In many studies model building procedures, such as variable selection, is undertaken on complete-case datasets, even where MI has been used. This is an emerging field of research but generally this approach should be avoided as the results can be biased and lack power.^{90,91} Alternative approaches such as averaging the results over all imputed datasets are available but are complex to implement and would require expert statistical support. Ultimately, we suggest that where the proportion of missing predictors or outcomes becomes too large (for example, more than 40%)⁹² this may prohibit meaningful model development and anything more than exploratory analysis.

6. *Predictor selection during modelling*

If there are too many candidate predictors it will be necessary to reduce the number to those with the most predictive utility. This process may seem strange to those more familiar with explanatory modelling but emphasizes the pragmatic characteristic of predictive modelling favouring usability and parsimony (Table 1). Therefore if a PRM is to be used in everyday

oncology nursing practice, it will often be necessary to reduce the number of candidate predictors from a long list (e.g. more than 20) to a more manageable number determined by PPI and stakeholder engagement to reduce burden for both staff and patients. As described, predictor selection prior to modelling is important and should be informed by processes 1, 2 and 5. However, often further reduction is required to ensure the PRM is reliable, generalizable and usable.^{8,40,93} A commonly used but flawed approach to variable selection in this context is stepwise regression, where inclusion of variables in a model is based on some pre-determined criteria such as p values below a threshold, and less commonly AIC or BIC. However, over the last two decades the arguments against its use have grown and stepwise regression is not recommended by many leading statisticians despite its continued use.^{40,94} See Harrell⁴⁰ for an excellent overview of the problems with stepwise regression.

Often univariate regression screening has been used to determine potential predictors, as indicated by F test or α above a certain threshold (e.g. 0.1).²⁷ However, for the purposes of predictive as opposed to explanatory modelling, this has been criticised as just another form of stepwise selection '*through the backdoor*' leading to overfitted estimates and biased error.²⁷ Part of the problem is that this approach ignores the fact that predictors do not exist in isolation from each other. Another problem with such approaches is that predictors shown to be important in previous research may not be included if they fail to reach thresholds (perhaps affecting the acceptability and generalisability of the model).⁴²

Whilst univariate screening may be a reasonable approach when the purpose of the modelling is explanatory, for predictive modelling modern regularisation techniques provide a more appropriate and powerful approach. In summary these approaches help to minimise prediction error and overfitting of data by reducing the coefficients by introducing a penalty

term to the regression. An advantageous technique to be aware of is Least Absolute Shrinkage and Selection Operator (LASSO)⁷⁵, which introduces a penalty term equal to the sum of absolute coefficient, meaning all coefficients are reduced and some reduced to zero. When used for variable selection, variables with non-zero coefficients after the shrinkage process are selected to be part of the model⁷⁸ and those with values of zero are effectively dropped. This helps develop more parsimonious models, can also afford a higher events-to-predictor ratio (e.g. ≤ 5) and overcome the limitations associated with highly correlated variables, which in our experience can be common in research involving patient reported outcomes and quality of life measures (e.g. high variance and Betas). However, even if using shrinkage techniques such as LASSO, those candidate predictors with a strong case for inclusion as suggested by Process 2 (reviewing current knowledge and clinical practice) should be included in the model.⁴² New approaches by which to apply these techniques to MI data are being explored⁹⁵ but require expertise statistical support to implement.

Interactions between potential predictors should be explored but should be pre-specified if analysis is exploratory or limited to those with evidence from wider literature to avoid spurious associations. Although often, for ease of use in clinical practice, interactions tend to be excluded from final models (because models assume effects of all predictors are additive)²⁷ with the increasing development and availability of online/mobile tools for calculating risk, the use of interaction terms will become increasingly feasible and so should be considered if they improve model performance.

7. *Assessing model performance*

It is important that the assumptions and appropriateness of the PRM are examined. This can be undertaken by defining residuals (i.e. the error in the model) and examining residual plots

⁹⁶, and performance can be assessed for discrimination (ability to correctly distinguish those with/without outcome) and calibration (predicted probability is in line with observed outcomes). In development studies the focus would usually be on discrimination, because, by definition, models will usually be well calibrated on the dataset in which they are developed.⁵¹ Specific assessment approaches will be determined by the model type. For example, linear regression's overall performance will often be assessed using R^2 to establish the variance explained by the model.^{51,97} Calibration can be assessed using root mean square error (RMSE, difference between values predicted by the model and the observed values) and visually using locally weighted scatterplot smoothing (LOWESS) and other calibration plots²⁷.

For logistic regression models, discrimination can be assessed with area under the receiver operating curve (ROC, similar to c-index for binary outcomes), pseudo R^2 or equivalent tests.²⁹ It can be useful to determine the models overall correct classification percentage, sensitivity (true positive rate), specificity (true negative rate), positive predictive values and negative predictive values. Calibration can be assessed by plotting the observed proportion of events against the predicted risk by groups defined by ranges of individual predicted risks and using goodness-of-fit Hosmer-Lemeshow or equivalent tests.^{29,51}

It is worth noting that while these traditional performance statistics assess accuracy, they provide no information the consequences of using the model in practice. Newer techniques such as decision curve analysis (DCA) can be used to assess the potential benefits and costs of using the model, by evaluating the clinical consequence of using the model to intervene or not.^{98,99} Importantly DCA provides an estimate of net benefit (NB) which combines the number of true positives and false positives, weighted by a factor of false positives relative to

false negatives, into a net number (similar to net profit) where the larger the number the better the model. This is plotted against a range of probability thresholds which is important because it is possible to consider patient preferences for risk. Therefore, if a PRM is ever planned to be used in clinical decision-making, an assessment of DCA is recommended although not yet common in practice.^{51,97} For an introduction to the basic principles of DCA see Vickers et al.¹⁰⁰

8. *Provide a clear rationale if using risk grouping*

Predictive risk models are often used to identify risk groupings, individuals at low, moderate or high risk of an outcome, through calculation of risk score/algorithm or index. At this stage the model can be simplified and appropriate cut-offs determined based on best practice regarding predictive accuracy and clinical utility.⁴⁰ Such approaches are tempting when using PROMs (e.g. cancer patients referred for support group if they score above a certain threshold) however, researchers should be cautious as a cut-off can quickly become standard practice without any clear rationale. Further in practice it is often assumed that individuals within each group have equivalent risk but in reality, there can be considerable diversity which can lead to sub-optimal care not in the best interests of patients.⁵¹ It is therefore important to provide details on how the risk groups are defined with rationales to avoid arbitrary decisions.⁵¹

9. *Undertake internal model validation*

The process in the model development phase involves internal validation using cross-validation, splitting the sample or hold-out samples, or bootstrap validation to avoid overfitting. For smaller studies ($n < 1000$) typical in psychosocial oncology, we suggest using bootstrapping as it attempts to account for model overfitting or uncertainty in the entire

model development process by generating a new sample of data from the original sample. Hence with limited sample size bootstrapping can be superior to other approaches as it uses *all* available data (unlike cross-validation or split-sample validation).⁵¹ The importance of this often-overlooked process is to estimate the bias in the model and therefore 'test' its predictive power in a 'new' sample.

All PRM development and internal validation should be reported in line with established guidelines provided by the transparent reporting of multivariable prediction model for individual prognosis or diagnosis (TRIPOD) statement.⁵¹

After the model development phase: external validation and evaluating clinical performance

PRM tend to perform less well in completely new samples and can perform differently in new clinical contexts and populations.²⁷ Testing models in new samples, known as external validation, allows for generalisability to be fully understood and test adaptations/extensions to an existing model. We are not aware of any such studies for applied PRM in psychosocial and supportive oncology research. Similarly, there is a lack of research evaluation of PRM clinical performance and implementation in practice.^{27,44} This is important because even where models are well developed, they might still not lead to improvements in patient outcomes and experience,¹⁰¹ and so it is important that future research evaluates their efficacy and effectiveness rather than assumes they will lead to improvements. We are unaware of any impact studies (evaluating PRM use in clinical practice) in psychosocial oncology.

Discussion

We have collated and presented a succinct summary of best practice research for PRMs to assist researchers and help them navigate the vast and sometimes conflicting literature available. While these recommendations for best practice in developing predictive risk models are available there appears to be relatively little application within psychosocial oncology and supportive care. If high quality PRM are to be safely deployed as part of routine practice there needs to be greater awareness of the quality standards and our framework aims to raise awareness of some of the key processes for best practice in predictive risk model development in the context of oncology nursing.

Over the next decade the delivery of cancer care, particularly in follow-up and survivorship phases, will be re-orientated away from hospital-settings, towards the community and stratified follow-up approaches for people with the most common cancer¹⁰² and this is likely to accelerate post-Covid-19. Follow up care will increasingly comprise remote monitoring and personalised supported self-management for a large (low risk of recurrence) majority. The use of risk prediction in oncology nursing practice offers exciting opportunities that are yet to be realised, to offer patients more personalised, responsive supportive cancer care. However, PRM use presents some intrinsically linked key challenges where oncology nurses are particularly well placed to lead the research agenda and practice debate including:

- **Ensuring PRM are developed for areas that are important to people affected by cancer.** Oncology nurses' holistic approach to care means they are well placed to inform the research agenda by ensuring models are predicting outcomes that truly make difference to patients' quality of life and wellbeing into survivorship.
- **Good communication and understanding of PRM.** Predicted probabilities and percentages are often misunderstood¹⁰³⁻¹⁰⁵ even amongst health professionals.¹⁰⁶

Oncology nurses have skills and training in advanced communication skills and are particularly well placed to develop and deliver strategies to ensure PRM are used in a way that can be widely understood and to allow for genuine choice and patient-preference in decision-making regarding psychosocial and supportive care options .

- **Ethical care as the focus of PRM.** Understanding how and when PRM can be used in an ethical way is a key challenge. As with psychosocial screening,^{24,107} PRM will only be helpful if services have clear pathways for care and self-management advice that are fit for purpose to meet patients' needs, particularly of those identified as 'higher risk'

PRM have the potential to be used to complement clinical practice and could be linked with existing holistic needs assessment and digital systems for symptom monitoring. In the future routinely collected digital patient reported predictors and outcomes could be used to facilitate the use of real-time PRM in practice to enhance the quality of life through stratified supportive care packages.

However, the failure to develop predictive risk model using best evidence and deployment without proper testing can cause great harm. If properly developed and validated predictive risk models have the potential to enhance supportive oncology care through harnessing routine digital collection of patient reported outcomes and the targeting of interventions according to risk characteristics.

References

1. Legg MJ. What is psychosocial care and how can nurses better provide it to adult oncology patients. *Australian Journal of Advanced Nursing (Online)*. 2011;28(3):61.
2. Fitch MI. Psychosocial management of patients with recurrent ovarian cancer: treating the whole patient to improve quality of life. *Seminars in Oncology Nursing*. 2003;19:40-53.
3. Mitchell AJ, Hussain N, Grainger L, Symonds P. Identification of patient-reported distress by clinical nurse specialists in routine oncology practice: a multicentre UK study. *Psycho-Oncology*. 2011;20(10):1076-1083.
4. Mitchell AJ, Lord K, Slattery J, Grainger L, Symonds P. How feasible is implementation of distress screening by cancer clinicians in routine clinical care? *Cancer*. 2012;118(24):6260-6269.
5. Maguire R, Fox PA, McCann L, et al. The eSMART Study Protocol: A Randomised Controlled Trial to Evaluate Electronic Symptom Management Using the Advanced Symptom Management System (ASyMS) Remote Technology for Patients with Cancer. *BMJ Open*. 2017.
6. Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. *Jama*. 2017;318(2):197-198.
7. Steyerberg EW, Moons KG, van der Windt DA, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. *PLoS Med*. 2013;10(2):e1001381.
8. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. *Bmj*. 2009;338:b606.
9. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how? *Bmj*. 2009;338:b375.
10. Hutchings HA, Evans BA, Fitzsimmons D, et al. Predictive risk stratification model: a progressive cluster-randomised trial in chronic conditions management (PRISMATIC) research protocol. *Trials*. 2013;14(1):301.
11. Tolles J, Meurer WJ. Logistic regression: relating patient characteristics to outcomes. *JAMA*. 2016;316(5):533-534.
12. Lee A, Mavaddat N, Wilcox AN, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. *Genetics in Medicine*. 2019;21(8):1708-1718.
13. Haybittle J, Blamey R, Elston C, et al. A prognostic index in primary breast cancer. *British journal of cancer*. 1982;45(3):361.
14. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. *Breast cancer research and treatment*. 1992;22(3):207-219.
15. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. *Journal of Clinical Oncology*. 2005;23(12):2716-2725.
16. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. *Journal of clinical oncology*. 2001;19(4):980-991.
17. Hippisley-Cox J, Coupland C. Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort study. *Bmj*. 2017;357.
18. Harris J, Cornelius V, Ream E, Cheevers K, Armes J. Anxiety after completion of treatment for early-stage breast cancer: a systematic review to identify candidate predictors and evaluate multivariable model development. *Supportive Care in Cancer*. 2017:1-13.
19. Kumar S, Rana ML, Verma K, et al. PrediQt-Cx: post treatment health related quality of life prediction model for cervical cancer patients. *PLoS one*. 2014;9(2):e89851.
20. Beltran-Alacreu H, López-de-Uralde-Villanueva I, Calvo-Lobo C, et al. Prediction models of health-related quality of life in different neck pain conditions: a cross-sectional study. *Patient preference and adherence*. 2018;12:657-666.

21. Révész D, van Kuijk SMJ, Mols F, et al. Development and internal validation of prediction models for colorectal cancer survivors to estimate the 1-year risk of low health-related quality of life in multiple domains. *BMC Medical Informatics and Decision Making*. 2020;20(1):54.
22. Watson E, Rose PW, Neal RD, et al. Personalised cancer follow-up: risk stratification, needs assessment or both? *British journal of cancer*. 2012;106(1):1-5.
23. Hingorani AD, van der Windt DA, Riley RD, et al. Prognosis research strategy (PROGRESS) 4: stratified medicine research. 2013.
24. Heathcote LC, Goldberg DS, Eccleston C, et al. Advancing shared decision making for symptom monitoring in people living beyond cancer. *The Lancet Oncology*. 2018;19(10):e556-e563.
25. LeBlanc TW. Shared Decision-making in Acute Myeloid Leukemia. *Seminars in Oncology Nursing*. 2019;35(6):150958.
26. Taylor C, Finnegan-John J, Green JS. "No decision about me without me" in the context of cancer multidisciplinary team meetings: a qualitative interview study. *BMC health services research*. 2014;14(1):488.
27. Steyerberg EW. *Clinical prediction models: a practical approach to development, validation, and updating*. Springer Science & Business Media; 2008.
28. de Leeuw J, Larsson M. Nurse-led follow-up care for cancer patients: what is known and what is needed. *Supportive Care in Cancer*. 2013;21(9):2643-2649.
29. Royston P, Moons KGM, Altman DG, Vergouwe Y. Prognosis and prognostic research: Developing a prognostic model. *Bmj*. 2009;338.
30. Shmueli G. To explain or to predict? *Statistical science*. 2010;25(3):289-310.
31. Yarkoni T, Westfall J. Choosing prediction over explanation in psychology: Lessons from machine learning. *Perspectives on Psychological Science*. 2017;12(6):1100-1122.
32. Wynants L, Van Calster B, Bonten MM, et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. *Bmj*. 2020;369.
33. Grimes DA. Epidemiologic Research Using Administrative Databases: Garbage In, Garbage Out. *Obstetrics & Gynecology*. 2010;116(5).
34. Chan MK, Bhatti H, Meader N, et al. Predicting suicide following self-harm: systematic review of risk factors and risk scales. *The British Journal of Psychiatry*. 2016;209(4):277-283.
35. Mulder R, Newton-Howes G, Coid JW. The futility of risk prediction in psychiatry. *The British Journal of Psychiatry*. 2016;209(4):271-272.
36. Gillingham P. Predictive risk modelling to prevent child maltreatment: insights and implications from Aotearoa/New Zealand. *Journal of public child welfare*. 2017;11(2):150-165.
37. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMC medicine*. 2015;13(1):1.
38. Hemingway H, Croft P, Perel P, et al. Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. 2013.
39. Hayden JA, van der Windt DA, Cartwright JL, Că P, Bombardier C. Assessing bias in studies of prognostic factors. *Annals of internal medicine*. 2013;158(4):280-286.
40. Harrell F. *Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis*. Springer; 2015.
41. Kuhn M, Johnson K. *Applied predictive modeling*. Vol 26: Springer; 2013.
42. Kattan MW, Gerds TA. A framework for the evaluation of statistical prediction models. *Chest*. 2020;158(1):S29-S38.
43. Kattan MW, Hess KR, Amin MB, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. *CA: A Cancer Journal for Clinicians*. 2016;66(5):370-374.

44. Vickers AJ. Prediction models in cancer care. *CA: a cancer journal for clinicians*. 2011;61(5):315-326.
45. Hempel C, Oppenheim P. Studies in the logic of explanation. *Philosophy of Science*. 1948;15(2):135-175.
46. Pursell E, While A. P= nothing, or why we should not teach healthcare students about statistics. *Nurse education today*. 2011;31(8):837-840.
47. STARD-AI Extension: Reporting Guidelines for Diagnostic Accuracy Studies Evaluating Artificial Intelligence Interventions. 2019; <https://www.equator-network.org/library/reporting-guidelines-under-development/reporting-guidelines-under-development-for-other-study-designs/#STARD-AI-Abs>.
48. STARD-AI for Abstracts Extension: Reporting Guidelines for Diagnostic Accuracy Studies Evaluating Artificial Intelligence Interventions. 2020; <https://www.equator-network.org/library/reporting-guidelines-under-development/reporting-guidelines-under-development-for-other-study-designs/#STARD-AI-Abs>. Accessed 12.09.2020, 2020.
49. Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension. *Bmj*. 2020;370:m3210.
50. Riley RD, Ensor J, Snell KI, et al. Calculating the sample size required for developing a clinical prediction model. *Bmj*. 2020;368.
51. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): explanation and elaboration. *Annals of internal medicine*. 2015;162(1):W1-W73.
52. Moons KG, de Groot JA, Bouwmeester W, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. *PLoS Med*. 2014;11(10):e1001744.
53. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. *Statistics in Medicine*. 2006;25(1):127-141.
54. Pavlou M, Ambler G, Seaman SR, et al. How to develop a more accurate risk prediction model when there are few events. 2015.
55. Bours MJ, van der Linden BW, Winkels RM, et al. Candidate Predictors of Health-Related Quality of Life of Colorectal Cancer Survivors: A Systematic Review. *Oncologist*. 2016;21(4).
56. Hayden JA, Côté P, Bombardier C. Evaluation of the Quality of Prognosis Studies in Systematic Reviews. *Annals of Internal Medicine*. 2006;144(6):427-437.
57. Hayden JA, Chou R, Hogg-Johnson S, Bombardier C. Systematic reviews of low back pain prognosis had variable methods and results—guidance for future prognosis reviews. *Journal of Clinical Epidemiology*. 2009;62(8):781-796.e781.
58. Iorio A, Spencer FA, Falavigna M, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. *Bmj*. 2015;350.
59. Staniszewska S, Brett J, Mockford C, Barber R. The GRIPP checklist: strengthening the quality of patient and public involvement reporting in research. *Int J Technol Assess Health Care*. 2011;27.
60. Staniszewska S, Brett J, Simera I, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. *Research Involvement and Engagement*. 2017;3(1):13.
61. Murphy M, Black N, Lamping D, et al. Consensus development methods, and their use in clinical guideline development. *Health technology assessment (Winchester, England)*. 1998;2(3):i-88.
62. Peat G, Riley RD, Croft P, et al. Improving the transparency of prognosis research: the role of reporting, data sharing, registration, and protocols. *PLoS Med*. 2014;11(7):e1001671.

63. Benchimol EI, Smeeth L, Guttman A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLOS Medicine*. 2015;12(10):e1001885.
64. Hendriksen J, Geersing G, Moons K, De Groot J. Diagnostic and prognostic prediction models. *Journal of Thrombosis and Haemostasis*. 2013;11:129-141.
65. Collins GS, Ogundimu EO, Cook JA, Manach YL, Altman DG. Quantifying the impact of different approaches for handling continuous predictors on the performance of a prognostic model. *Statistics in Medicine*. 2016;35(23):4124-4135.
66. Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per independent variable in proportional hazards analysis I. Background, goals, and general strategy. *Journal of clinical epidemiology*. 1995;48(12):1495-1501.
67. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. *Journal of clinical epidemiology*. 1995;48(12):1503-1510.
68. Riley RD, Snell KI, Ensor J, et al. Minimum sample size for developing a multivariable prediction model: PART II-binary and time-to-event outcomes. *Statistics in medicine*. 2019;38(7):1276-1296.
69. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. *American journal of epidemiology*. 2007;165(6):710-718.
70. van Smeden M, de Groot JA, Moons KG, et al. No rationale for 1 variable per 10 events criterion for binary logistic regression analysis. *BMC medical research methodology*. 2016;16(1):163.
71. van Smeden M, Moons KG, de Groot JA, et al. Sample size for binary logistic prediction models: beyond events per variable criteria. *Statistical methods in medical research*. 2019;28(8):2455-2474.
72. Riley RD, Snell KI, Ensor J, et al. Minimum sample size for developing a multivariable prediction model: Part I—Continuous outcomes. *Statistics in medicine*. 2019;38(7):1262-1275.
73. Hoerl AE, Kennard RW. Ridge Regression: Biased Estimation for Nonorthogonal Problems. *Technometrics*. 1970;12(1):55-67.
74. Hoerl AE, Kennard RW. Ridge regression: applications to nonorthogonal problems. *Technometrics*. 1970;12(1):69-82.
75. Tibshirani R. Regression shrinkage and selection via the lasso. *Journal of the Royal Statistical Society Series B (Methodological)*. 1996:267-288.
76. Zou H, Hastie T. Regression shrinkage and selection via the elastic net, with applications to microarrays. *JR Stat Soc Ser B*. 2003;67:301-320.
77. McNeish DM. Using Lasso for Predictor Selection and to Assuage Overfitting: A Method Long Overlooked in Behavioral Sciences. *Multivariate Behavioral Research*. 2015;50(5):471-484.
78. Fonti V, Belitser E. *Feature Selection using LASSO*. VU Amsterdam; 30/03/2017 2017.
79. Smith GD, Ebrahim S. Data dredging, bias, or confounding. *BMJ (Clinical research ed)*. 2002;325(7378):1437-1438.
80. Hiemstra B, Keus F, Wetterslev J, Glud C, van der Horst IC. DEBATE-statistical analysis plans for observational studies. *BMC Medical Research Methodology*. 2019;19(1):233.
81. Murthy VH, Krumholz HM, Gross CP. Participation in Cancer Clinical Trials Race-, Sex-, and Age-Based Disparities. *JAMA*. 2004;291(22):2720-2726.
82. Bell ML, Fairclough DL. Practical and statistical issues in missing data for longitudinal patient-reported outcomes. *Statistical methods in medical research*. 2014;23(5):440-459.
83. Bell ML, Fairclough DL, Fiero MH, Butow PN. Handling missing items in the Hospital Anxiety and Depression Scale (HADS): a simulation study. *BMC research notes*. 2016;9(1):479.
84. Bell ML, Fiero M, Horton NJ, Hsu C-H. Handling missing data in RCTs; a review of the top medical journals. *BMC medical research methodology*. 2014;14(1):118.

85. Fielding S, Fayers PM, Ramsay CR. Investigating the missing data mechanism in quality of life outcomes: a comparison of approaches. *Health and Quality of Life Outcomes*. 2009;7(1):57.
86. Fielding S, Maclennan G, Cook JA, Ramsay CR. A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes. *Trials*. 2008;9(1):51.
87. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta psychiatrica scandinavica*. 1983;67(6):361-370.
88. Eekhout I, de Boer RM, Twisk JW, de Vet HC, Heymans MW. Missing data: a systematic review of how they are reported and handled. *Epidemiology*. 2012;23(5):729-732.
89. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? *International journal of methods in psychiatric research*. 2011;20(1):40-49.
90. White IR, Royston P, Wood A. Multiple imputation using chained equations: issues and guidance for practice. *Stat Med*. 2011;30.
91. Wood AM, White IR, Royston P. How should variable selection be performed with multiply imputed data? *Statistics in medicine*. 2008;27(17):3227-3246.
92. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. *BMC medical research methodology*. 2017;17(1):162-162.
93. Subramanian J, Simon R. Overfitting in prediction models—is it a problem only in high dimensions? *Contemporary clinical trials*. 2013;36(2):636-641.
94. Flom PL, Cassell DL. Stopping stepwise: Why stepwise and similar selection methods are bad, and what you should use. Paper presented at: NorthEast SAS Users Group Inc 20th Annual Conference: 11-14th November 2007; Baltimore, Maryland 2007.
95. Musoro JZ, Zwinderman AH, Puhan MA, ter Riet G, Geskus RB. Validation of prediction models based on lasso regression with multiply imputed data. *BMC Medical Research Methodology*. 2014;14(1):116.
96. Acock AC. *A gentle introduction to Stata*. Stata press; 2008.
97. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for some traditional and novel measures. *Epidemiology (Cambridge, Mass)*. 2010;21(1):128.
98. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Medical Decision Making*. 2006;26(6):565-574.
99. Vickers AJ, Cronin AM. Everything you always wanted to know about evaluating prediction models (but were too afraid to ask). *Urology*. 2010;76(6):1298-1301.
100. Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. *Diagnostic and Prognostic Research*. 2019;3(1):18.
101. Connell A, Raine R, Martin P, et al. Implementation of a Digitally Enabled Care Pathway (Part 1): Impact on Clinical Outcomes and Associated Health Care Costs. *Journal of medical Internet research*. 2019;21(7):e13147.
102. England N. Long Term Plan 2019; www.england.nhs.uk/long-term-plan.
103. Han PK, Klein WM, Lehman TC, Massett H, Lee SC, Freedman AN. Laypersons' responses to the communication of uncertainty regarding cancer risk estimates. *Medical Decision Making*. 2009;29(3):391-403.
104. Han PKJ, Lehman TC, Massett H, Lee SJC, Klein WMP, Freedman AN. Conceptual problems in laypersons' understanding of individualized cancer risk: a qualitative study. *Health Expectations*. 2009;12(1):4-17.
105. Gigerenzer G, Galesic M. Why do single event probabilities confuse patients? *Bmj*. 2012;344:e245.

106. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S. Helping doctors and patients make sense of health statistics. *Psychological science in the public interest*. 2007;8(2):53-96.
107. Meijer A, Roseman M, Delisle VC, et al. Effects of screening for psychological distress on patient outcomes in cancer: A systematic review. *Journal of Psychosomatic Research*. 2013;75(1):1-17.

Tables

Table 1 Six key characteristics of predictive risk models	
Characteristic	Explanation
Longitudinal data	In predictive modelling use of longitudinal data is required i.e. where the outcome occurs at a later calendar date than the predictors. Models are constructed for predicting outcomes based on predictors available at a baseline. The number of individuals in the dataset is of key importance in order to be able to fit a suitable model, but it should be noted that standard power calculations for determining sample size are not appropriate.
Pragmatic considerations are important	Models need to be acceptable to patients and usable in clinical practice with a feasible number of predictors which have the potential to be easily collected (for example between 2 and 20)
The bias-variance trade-off	In explanatory modelling the focus is on minimising bias to obtain accurate representation of the underlying theory. ³⁰ In comparison, predictive modelling seeks to minimise the combination of bias and estimation variance, occasionally sacrificing the accuracy for improved precision and usefulness in practice.
Avoid overfitting the model to the data	Models should avoid overfitting, meaning where data closely follow a set of data points, this helps with generalizability. Typically, models are not applicable to new patient samples, even in similar populations or when the setting is very similar to the original setting and this is often because the original model has been fitted to reflect the idiosyncrasies in the data. The impact of overfitting can be reduced with modern statistical techniques (see Process 6)
Calibration and discrimination are important	Calibration refers to whether the models predicted probability is in line with observed outcomes and discrimination refers to the model's ability to correctly distinguish those with/without outcome. Both should be assessed. For PRM to be used in oncology nursing practice they need to be sufficiently reliable. This means that there should be concordance between the predicted and observed outcomes and for example the PRM discriminates between those who are higher and lower risk patients.
Model validation is vital	Validation matters in a similar way to the development and testing of questionnaires or patient reported outcome measures (PROMs) used in oncology nursing practice. Before a predictive model is used to inform decision-making, it should be validated, at least using so-called internal validation (assessing performance in a bootstrap sample, using cross-validation or split-sample ('hold-out') validation,

see Process 9). Even better, an external sample or pilot, and evaluation of clinical performance in real-world practice. We have found a void in current psychosocial oncology literature evaluating performance using either resampling or in new samples.

Table 2 Summary of guide to good practice for predictive risk model development

Stage 1 Preparation for modelling	
Processes (and sub-process, where relevant)	Details
1. <i>Choosing and defining an outcome</i>	<ul style="list-style-type: none"> Identify a clinically relevant and patient focused outcome to be predicted Define its key parameters including suitable methods of valid and reliable measurement, type of outcome (single/combined) and time-horizon including duration, if relevant, the number and timing of measurement and timing of outcome occurrence
2. <i>Reviewing current knowledge and clinical practice</i>	<p>Used to identify potential predictors this should include (but not be limited to):</p> <ul style="list-style-type: none"> Undertake a systematic literature review &/or meta-analysis. Stakeholder and patient involvement.
3. <i>Assessing the data quality</i>	<ul style="list-style-type: none"> Data should be longitudinal and comprehensive. Sample size is important.
3.1 <i>Longitudinal design and data sources</i>	<ul style="list-style-type: none"> PRM should be developed using longitudinal (prospective or retrospective) designs only using either original research or secondary analysis. The sample includes people at risk of developing outcome of interest. PRM include multiple candidate predictors measured at an appropriate 'baseline'. Outcome(s) are measured after a sufficient interval (time-horizons). Measures should be valid/reliable for target population.
3.2 <i>Candidate predictors</i>	<ul style="list-style-type: none"> Candidate predictors/outcome(s) can be interval, ordinal or nominal.

Table 2 Summary of guide to good practice for predictive risk model development	
Stage 1 Preparation for modelling	
Processes (and sub-process, where relevant)	Details
	<ul style="list-style-type: none"> When developing models the conversion of continuous predictors/outcome(s)(e.g. age) to categorical (e.g. age group) should be avoided.
<i>3.3 Sample size</i>	<ul style="list-style-type: none"> An appropriate sample size is required in terms of the number of participants relative to the number of candidate predictors.
<i>3.4 Establish type of multivariable regression method</i>	<ul style="list-style-type: none"> The outcome of interest will determine the type of regression model to use. Typical models include linear (for continuous outcomes) logistic (for binary outcomes) and Cox's (time to event).
Stage 2 Analysis and modelling	
<i>4. Assess data quality</i>	<ul style="list-style-type: none"> Examine descriptive statistics and characteristics of the sample. Explore amount/patterns of missingness. Failure to assess this may result in biased prediction models.
<i>5. Handle missing data</i>	<ul style="list-style-type: none"> Missing data can occur at different levels including for the baseline or outcome, or at item and scale level. If simultaneously missing data is $\geq 5\%$ avoid case-wise deletion, mean or single imputation, which reduce data and increase bias. Often Multiple Imputation using Chained Equations (MICE) sensitivity analysis will be the best approach. MICE regressions include all predictors of missing data and any predictors/outcome(s) from final analysis model. MICE 'rule of thumb': impute the number of datasets equivalent to the percentage of missing data.
<i>6. Predictor selection during modelling</i>	<p>PRIOR TO MODELLING this is informed by:</p> <ul style="list-style-type: none"> Systematic review +/- meta analysis Expert opinion/clinical practice/ patient public involvement Data quality/availability Avoid selection based on significant P values <p>DURING MODELLING:</p> <ul style="list-style-type: none"> Strong evidence base or specific research question: test full model (no selection) Exploratory research & many candidate predictors: consider penalised regressions. If selection of predictors is necessary, <u>avoid</u> selection using stepwise regression or p-value screening.
<i>7. Assessing model performance</i>	<ul style="list-style-type: none"> Assess overall performance for example using R^2 (to describe the variance explained) and residual vs. fitted plots (assessment of bias). Assess discrimination (ability to correctly distinguish those with/without outcome) and concordance statistics. Assess calibration (predicted probability is in line with observed outcomes) for example using root mean squared error (RMES,

Table 2 Summary of guide to good practice for predictive risk model development	
Stage 1 Preparation for modelling	
Processes (and sub-process, where relevant)	Details
	<p>the standard deviations of the residuals), calibration plots and the area under the receiver operating curve (ROC).</p> <ul style="list-style-type: none"> • Assess clinical utility and cost/benefits of using the model to inform practice with decision curve analysis (DCA)
8. <i>Provide a clear rationale if using risk grouping</i>	<ul style="list-style-type: none"> • If using, model may be simplified, and appropriate cut-offs determined for risk grouping. • Caution should be used in applying arbitrary cut-offs as this may lead to sub-optimal care. • The rationale for any risk grouping should be clearly described.
9. <i>Undertake internal model validation</i>	<ul style="list-style-type: none"> • Use split samples, cross-validation or Bootstrap validation to avoid overfitting (i.e. over-optimistic model performance). • Bootstrapping is often appropriate in psychosocial oncology and supportive care research. • Use the TRIPOD statement to report model development.